Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

Auteurs : Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A
Année : 2013
Journal : Invest New Drugs
Volume : 31(4)
Pages : 959-66

Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?

Auteurs : Gombos A, Metzger-Filho O, Dal Lago L, Awada A
Année : 2012
Journal : Invest New Drugs
Volume : 30(6)
Pages : 2433-42

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Auteurs : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Année : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74

Second primary cancers in head and neck cancer patients: a challenging entity.

Auteurs : de Castro G, Awada A
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 203-4

Clinical development of new formulations of cytotoxics in solid tumors.

Auteurs : Azim HA, Awada A
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 325-31

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Auteurs : Awada A, Vandone AM, Aftimos P
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 297-304

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Auteurs : Awada A, Bozovic-Spasojevic I, Chow L
Année : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pages : 494-504

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Année : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pages : 1149-59

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Auteurs : Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L
Année : 2012
Journal : Breast
Volume : 21(4)
Pages : 507-13

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Année : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pages : 897-905

Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives.

Auteurs : Akasbi Y, Awada A, Arifi S, Mellas N, El Mesbahi O
Année : 2012
Journal : Bull Cancer
Volume : 99(10)
Pages : 92-9

EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

Auteurs : Lalami Y, Specenier PM, Awada A, Lacombe D, Liberatoscioli C, Fortpied C, El-Hariry I, Bogaerts J, Andry G, Langendijk HJ, Vermorken JB
Année : 2012
Journal : Radiother Oncol
Volume : 105(2)
Pages : 238-40

Prevention and management of major side effects of targeted agents in breast cancer.

Auteurs : Metzger Filho O, Saini KS, Azim HA, Awada A
Année : 2012
Journal : Crit Rev Oncol Hematol
Volume : 84(1)
Pages : e79-85

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

Auteurs : Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T, De Santis M
Année : 2012
Journal : Med. Oncol.
Volume : 29(3)
Pages : 1896-1907

Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.

Auteurs : Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart-Gebhart M, Flamen P
Année : 2012
Journal : Ann Oncol
Volume : 23(7)
Pages : 1687-93

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Auteurs : Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G
Année : 2012
Journal : Eur. J. Cancer
Volume : 48(2)
Pages : 179-86

Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC).

Auteurs : Klastersky J, Awada A
Année : 2012
Journal : Crit Rev Oncol Hematol
Volume : 81(1)
Pages : 49-57

Clinical trial design in head and neck cancer: from past experiences to future perspectives.

Auteurs : de Castro G Jr, Henrique dos Anjos C, Lalami Y, Awada A
Année : 2012
Journal : Clinical Investigation
Volume : 2(5)
Pages : 473-481

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Auteurs : Berghmans T, Remmelink M, Awada A
Année : 2012
Journal : Lung Cancer : Targets and Therapy
Volume : 3
Pages : 91-99

Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.

Auteurs : Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, Awada A, Shamseddine A
Année : 2012
Journal : Crit Rev Oncol Hematol
Volume : 84(2)
Pages : 149-60